Scholar Rock Holding CORP

Scholar Rock announced first quarter 2026 financial results, highlighting the FDA's acceptance of the apitegromab Biologics License Application for spinal muscular atrophy with a PDUFA date of September 30, 2026.

Scholar Rock Holding Corporation has resubmitted its Biologics License Application for apitegromab for spinal muscular atrophy to the FDA, anticipating a late September 2026 action date.

Scholar Rock reported Q4 and full-year 2025 financial results, provided updates on apitegromab's regulatory path, and secured a new $550 million debt facility.

Scholar Rock reported full-year 2025 financial results, provided an update on its apitegromab regulatory pathway, and secured a new $550 million debt facility.

Scholar Rock Holding Corporation announced preliminary cash of $365 million and strategic priorities for 2026, focusing on apitegromab regulatory approvals and pipeline advancement.

Scholar Rock's manufacturing partner, Catalent Indiana, received an FDA warning letter, impacting the apitegromab launch timeline.

Scholar Rock Holding Corporation filed its Q1 2026 Form 10-Q, detailing a net loss of $105.5 million and a significant increase in G&A expenses, while also announcing the resubmission of its apitegromab BLA with a new PDUFA date.

Scholar Rock reported increased losses and a significant FDA Complete Response Letter for its lead SMA drug apitegromab, while securing additional debt financing and extending its cash runway into 2027.

Scholar Rock Holding Corporation reported increased net losses in Q2 2025 due to higher R&D and G&A expenses, while advancing its lead SMA drug, apitegromab, towards potential U.S. and European commercialization.

Scholar Rock Holding Corporation announces its Q1 2025 financial results, emphasizing the regulatory advancements of apitegromab for spinal muscular atrophy (SMA) and progress in its cardiometabolic and oncology programs.

Scholar Rock reports positive results from its Phase 3 SAPPHIRE trial for apitegromab in SMA and provides a financial update for the third quarter of 2024.

Scholar Rock's second quarter 2024 report details increased R&D spending, a net loss of $115.4 million for the first six months of the year, and ongoing clinical trials for their key drug candidates.

Scholar Rock's lead SMA drug, apitegromab, faces regulatory delays due to third-party manufacturing issues, while the company secures new financing and advances its pipeline.

Scholar Rock's pivotal Phase 3 SAPPHIRE trial achieved its primary endpoint, leading to a BLA submission to the FDA for apitegromab in spinal muscular atrophy.

Scholar Rock Holding Corporation reports its 2023 financial results, highlighting progress in its clinical programs and strategic focus.

Scholar Rock Holding Corp. director Jeffrey S. Flier sold shares valued at over $150,000 under a pre-arranged trading plan to cover tax obligations.

Scholar Rock Holding Corp. director Michael Gilman has sold shares of common stock totaling 2,544 units, executed under a pre-arranged Rule 10b5-1 trading plan.

Scholar Rock Holding Corp. director Kristina Burow reported the sale of common stock valued at approximately $113,000 under a pre-arranged trading plan.

Scholar Rock Holding Corp. director Joshua Reed reported the sale of common stock valued at over $100,000, executed under a pre-arranged trading plan.

Director Jeffrey S. Flier acquired 6,839 restricted stock units and 4,310 stock options in Scholar Rock Holding Corp.

Director Joshua Reed acquired 6,839 restricted stock units and 4,310 stock options as part of an annual equity compensation grant.

Scholar Rock Holding Corporation schedules its 2026 Annual Meeting of Stockholders for June 4, 2026, to address director elections, auditor ratification, and executive compensation.

Scholar Rock Holding Corporation withdraws a proposal to ratify the appointment of Ernst & Young LLP as its independent auditor after EY declined to stand for re-election.

Scholar Rock Holding Corporation announces the withdrawal of Jay T. Backstrom as a director nominee and several executive appointments ahead of its Annual Meeting of Stockholders on May 22, 2025.

Scholar Rock Holding Corporation's upcoming annual meeting on May 22, 2025, includes proposals for electing directors, ratifying the appointment of Ernst & Young LLP, and approving executive compensation.

Scholar Rock Holding Corporation will hold its 2025 Annual Meeting of Stockholders online on May 22, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.

Scholar Rock Holding Corporation is holding its annual meeting on June 27, 2024, seeking stockholder approval on director elections, auditor ratification, and amendments to the company's certificate of incorporation.

Samsara BioCapital entities and Dr. Srinivas Akkaraju updated their beneficial ownership in Scholar Rock Holding Corp. through a series of private and open market transactions.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.4% of Scholar Rock Holding Corp.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Scholar Rock Holding Corp following an internal corporate realignment.

Wellington Management Group LLP and its affiliates have disclosed a 5.6% beneficial ownership stake in Scholar Rock Holding Corporation as of December 31, 2025.

T. Rowe Price Associates, Inc. has disclosed an increased beneficial ownership of 7.2% in Scholar Rock Holding Corp. common stock.

T. Rowe Price Associates, Inc. has disclosed an increased passive beneficial ownership of 9.2% in Scholar Rock Holding Corp., holding 8,761,784 common shares as of June 30, 2025.

Redmile Group, LLC, along with its principal Jeremy C. Green and RedCo II Master Fund, L.P., has disclosed a significant beneficial ownership stake of 9.9% in Scholar Rock Holding Corporation, primarily through common stock and warrants, subject to a beneficial ownership limitation.